Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott suspends Indian physician ‘brand reminder’ plan amid growing industry scrutiny

This article was originally published in Scrip

Executive Summary

Abbott's decision to review the provision of free gifts to physicians in India has raised speculation that the company may be acting out of caution against a backdrop of growing scrutiny in the country and internationally against such inducements, which experts suggest more firms may be less inclined to pursue in future.

You may also be interested in...



Abbott’s Medical Camps In India: Genuine Effort or Proxy Sales Plan?

US multinational Abbott is under fire in India for allegedly using medical “camps” and a questionable “survey” approach to bolster prescriptions for its diabetic neuropathy drug, Surbex Star. Abbott has strongly denied any wrong-doing but some experts suggest it’s probably tough to delink the rub-off such activities could have on brand building.

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Merck KGaA Exec On Innovating Vaccine Manufacturing To Tackle Outbreaks

The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.

Topics

Related Companies

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel